2JAIN R,CHUNG S M, JAIN L,et al. Implications of obesity for drug therapy:limitations and challenges[J]. Clin Pharmacol Ther,2011;90(1):77-89.
3DAVIES-VOHBRODT S, ITO J I, TEGTMEIER BR, et al Vori- conazole serum concentrations in obese and overweight immunocom- promised patients: a retrospective review[J]. Pharmdcdtherapy, 2013,33(1):22-30.
4KOSELKE E,KRAFT S, SMITH J, et al. Evaluation of the effect of obesity on voriconazole serum concentrations[J]. J Antimicrob Che- mother,2012, 67(12):2957-2962.
5PAI M T P. Steady-state plasma pharmacokinetics of oral voricon- azole in obese adults[J]. Antimicrob Agents Chemother, 2011,55(6):2601-2605.
